RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


FORM 6-K
...

Related Keywords

China , Macao , Macau General , Macau , Washington , United States , Coted Ivoire , Israel , Uganda , Thailand , Bundibugyo , Hong Kong , United Kingdom , Taiwan , Tel Aviv , South Africa , Sudan , Ivory Coast , Dror Ben Asher , Jeffrey Kugelman , Reza Fathi , Redhill Biopharma , Adi Frish , Nasdaq , Us Department Of Defense , Gilead Sciences Inc , Us Army Ebola , Commission File No , Germany Heidelberg Pharmaceuticals , Exchange Commission On , Centers For Disease , Company Annual Report On Form , Product Development Pipeline , Corporate Business Development , Company Expanded Access Program , National Institutes Of Health , National Institute Of Allergy , Us Army Medical Research , Exchange Commission , Nuclear Countermeasures Program , Company Registration Statements On Form , Securities Exchange , Molecular Biology Division , Us Army Announce Opaganib , Redhill Biopharma Ltd , Us Army , Foreign Private Issuer , Securities Exchange Act , Regulationst Rule , Announce Opaganib , Registration Statements , Remdesivir Show Distinct Synergistic , Branch Chief Synthetic Biology , Medical Research Institute , Infectious Diseases , Acute Radiation Syndrome , Disease Control , Saharan Africa , National Institute , National Institutes , Orphan Drug , Heidelberg Pharmaceuticals , Medical Research , Hill Biopharma , Private Securities Litigation Reform Act , Nasdaq Capital Market , Development Pipeline , Expanded Access Program , Annual Report , Gilead Sciences , Markets ,